First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide

[1]  K. Houkin,et al.  The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in the patients with glioblastoma and anaplastic astrocytoma. , 2018, Journal of neurosurgical sciences.

[2]  F. Lieberman,et al.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.

[3]  Satoshi O. Suzuki,et al.  A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology , 2017, Neuropathology : official journal of the Japanese Society of Neuropathology.

[4]  Satoshi O. Suzuki,et al.  Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution , 2017, Brain Tumor Pathology.

[5]  Xianglin L. Du,et al.  Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study , 2017, Oncotarget.

[6]  T. Jiang,et al.  Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials , 2017, Oncotarget.

[7]  D. Osoba,et al.  Short‐Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma , 2017, The New England journal of medicine.

[8]  Satoshi O. Suzuki,et al.  Insular primary glioblastomas with IDH mutations: Clinical and biological specificities , 2017, Neuropathology : official journal of the Japanese Society of Neuropathology.

[9]  Satoshi O. Suzuki,et al.  Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status , 2017, OncoTargets and therapy.

[10]  W. Mason,et al.  Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. , 2016, Neuro-oncology.

[11]  Satoshi O. Suzuki,et al.  Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data , 2016, PloS one.

[12]  E. Miyaoka,et al.  A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas , 2016, Acta neuropathologica communications.

[13]  Y. Narita.  Bevacizumab for glioblastoma , 2015, Therapeutics and clinical risk management.

[14]  R. Bourgon,et al.  Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Shengping Yang,et al.  Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era , 2014, Cancer medicine.

[16]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[17]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[18]  J. Uhm,et al.  Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population‐based analysis , 2013, Cancer.

[19]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[20]  Satoshi O. Suzuki,et al.  Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue , 2011, Brain Tumor Pathology.

[21]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[22]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[23]  Y. Katayama,et al.  Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas , 2005, Journal of Neuro-Oncology.

[24]  Eilon D. Kirson,et al.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma , 2017 .

[25]  K. Arita,et al.  Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis. , 2017, Molecular and clinical oncology.

[26]  J. Schramm,et al.  TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. , 2015, Neuro-oncology.